Bone loss in the oestrogen‐depleted rat is not exacerbated by sitagliptin, either alone or in combination with a thiazolidinedione. Issue 10 (1st May 2013)
- Record Type:
- Journal Article
- Title:
- Bone loss in the oestrogen‐depleted rat is not exacerbated by sitagliptin, either alone or in combination with a thiazolidinedione. Issue 10 (1st May 2013)
- Main Title:
- Bone loss in the oestrogen‐depleted rat is not exacerbated by sitagliptin, either alone or in combination with a thiazolidinedione
- Authors:
- Cusick, T.
Mu, J.
Pennypacker, B. L.
Li, Z.
Scott, K. R.
Shen, X.
Fisher, J. E.
Langdon, R. B.
Kimmel, D. B.
Zhang, B. B.
Glantschnig, H. - Abstract:
- Abstract : Antihyperglycaemic therapy on bone was evaluated in the ovariectomized (OVX), non‐diabetic adult rat. Animals were treated daily for 12 weeks with various doses of sitagliptin, pioglitazone, rosiglitazone, combinations of sitagliptin with pioglitazone or vehicle alone. Sitagliptin target engagement was confirmed by assessing inhibition of plasma dipeptidyl peptidase‐4 (DPP‐4) and oral glucose tolerance. Parameters related to bone health were evaluated in femur and vertebrae by dual‐energy X‐ray absorptiometry and histomorphometry. Bone mineral density (BMD) generally did not differ significantly between OVX‐sitagliptin‐treated animals and OVX‐vehicle controls. In lumbar vertebrae, however, there was significantly less BMD loss with increasing sitagliptin dose. Thiazolidinedione (TZD) treatment generally resulted in lower BMD; OVX‐TZD‐treated (but not OVX‐sitagliptin‐treated) animals also had lessened cortical thickness in central femur and profoundly greater bone marrow adiposity in lumbar vertebrae. These findings support prior findings with TZDs and suggest a neutral or beneficial impact of DPP‐4 inhibition on bone health.
- Is Part Of:
- Diabetes, obesity & metabolism. Volume 15:Issue 10(2013:Oct.)
- Journal:
- Diabetes, obesity & metabolism
- Issue:
- Volume 15:Issue 10(2013:Oct.)
- Issue Display:
- Volume 15, Issue 10 (2013)
- Year:
- 2013
- Volume:
- 15
- Issue:
- 10
- Issue Sort Value:
- 2013-0015-0010-0000
- Page Start:
- 954
- Page End:
- 957
- Publication Date:
- 2013-05-01
- Subjects:
- antihyperglycaemic agent -- bone mineral density -- dipeptidyl peptidase‐4 inhibitor -- marrow adiposity -- peroxisome proliferator‐activated receptor‐γ agonist -- thiazolidinedione -- type 2 diabetes
Diabetes -- Periodicals
Obesity -- Periodicals
Metabolism -- Disorders -- Periodicals
Clinical pharmacology -- Periodicals
616.462 - Journal URLs:
- http://www.blackwellpublishing.com/journal.asp?ref=1462-8902&site=1 ↗
http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1463-1326 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/dom.12109 ↗
- Languages:
- English
- ISSNs:
- 1462-8902
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3579.601970
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 150.xml